# IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct05827796/  
OnCo record `nct05827796` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IN10018 and Gemcitabine in pancreatic ductal adenocarcinoma, run by InxMed (Shanghai) Co., Ltd., now recruiting.

## Summary

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05827796 by InxMed (Shanghai) Co., Ltd., with 70 participants planned, started 2022-12-08 and due to reach its primary completion in 2025-12-31. Interventions recorded: IN10018, Albumin-Bound Paclitaxel, Gemcitabine and KN046.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05827796
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018+Standard Chemotherapy and IN10018+Standard Chemotherapy+KN046 in Subjects With Advanced Pancreatic Cancer
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05827796: https://clinicaltrials.gov/study/NCT05827796

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [IN10018](https://onco.cc/drugs/in10018/)

---
JSON: https://onco.cc/api/v1/entities/nct05827796.json